Nancy Finnerty, MD
Family Medicine · Dade City, FLNPI 1275554412
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,067 and has fallen 51.2% since, to $521 in 2025.
Across 247 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$728
- Novo Nordisk$592
- GSK$325
- Amarin Pharma, Inc.$244
- Pfizer$239
- AstraZeneca$201
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,90699%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 48 | $728 |
| Novo Nordisk | 51 | $592 |
| GSK | 18 | $325 |
| Amarin Pharma, Inc. | 13 | $244 |
| Pfizer | 16 | $239 |
| AstraZeneca | 13 | $201 |
| Lilly USA, LLC | 13 | $193 |
| Exact Sciences | 10 | $161 |
| Merck | 7 | $126 |
| AbbVie(2 entities) | 6 | $125 |
| Novartis | 7 | $124 |
| Boehringer Ingelheim | 6 | $116 |
| Dynavax Technologies Corporation | 4 | $96 |
| Kowa Pharmaceuticals America, Inc. | 6 | $94 |
| Dexcom, Inc. | 4 | $92 |
| Bayer | 3 | $83 |
| Abbott | 5 | $81 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Astellas Pharma US Inc | 3 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
How this compares
$3,939 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $57,813 |
| EliquisApixaban | 34 | $49,147 |
| OzempicSemaglutide | 32 | $36,386 |
| Xtampza ErOxycodone Myristate | 23 | $34,692 |
| MounjaroTirzepatide | 27 | $27,660 |
| RybelsusSemaglutide | 17 | $23,163 |
| TrulicityDulaglutide | 11 | $21,464 |
| MyrbetriqMirabegron | 14 | $15,081 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $8,192 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $7,834 |
| InvokanaCanagliflozin | 13 | $7,477 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,974 |
| Oxycodone Hcl | 161 | $5,850 |
| LantusInsulin Glargine,hum.Rec.Anlog | 40 | $5,724 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 25 | $5,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $325 | $62,75087 claims |
| Novo NordiskOzempic, Rybelsus | $592 | $59,54949 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $193 | $54,16663 claims |
| PfizerEliquis | $239 | $49,14734 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $15,08114 claims |
| AstraZenecaSymbicort | $201 | $8,19220 claims |
| Johnson & JohnsonInvokana | $30 | $7,47713 claims |
| Boehringer IngelheimSpiriva Respimat | $116 | $5,97412 claims |
| Sanofi-aventis U.S. LLCLantus | $53 | $5,72440 claims |
| MerckBelsomra | $126 | $5,02012 claims |
| AbbVieSynthroid | $125 | $1,64327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Dade City
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.